The Role of the Immune Response in Age-Related Macular Degeneration
暂无分享,去创建一个
A. Dick | J. Atkinson | V. Holers | A. Sodhi | S. Whitcup | B. Rohrer | D. Sinha | Akrit Sodhi | Andrew D. Dick
[1] A. Nesburn,et al. Mitochondrial DNA Variants Mediate Energy Production and Expression Levels for CFH, C3 and EFEMP1 Genes: Implications for Age-Related Macular Degeneration , 2013, PloS one.
[2] B. Ksander,et al. NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration. , 2013, Investigative ophthalmology & visual science.
[3] J. P. McCoy,et al. Hypomethylation of the IL17RC promoter associates with age-related macular degeneration. , 2012, Cell reports.
[4] Santa Jeremy Ono,et al. Identification of anti-retinal antibodies in patients with age-related macular degeneration. , 2012, Experimental and molecular pathology.
[5] L. O’Neill,et al. Biochemical regulation of the inflammasome , 2012, Critical reviews in biochemistry and molecular biology.
[6] I. Bhutto,et al. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. , 2012, Molecular aspects of medicine.
[7] J. Sparrow,et al. Complement dysregulation in AMD: RPE-Bruch's membrane-choroid. , 2012, Molecular aspects of medicine.
[8] P. Morgado,et al. Complement Protein C1q Directs Macrophage Polarization and Limits Inflammasome Activity during the Uptake of Apoptotic Cells , 2012, The Journal of Immunology.
[9] W. Hauswirth,et al. DICER1 Loss and Alu RNA Induce Age-Related Macular Degeneration via the NLRP3 Inflammasome and MyD88 , 2012, Cell.
[10] J. Hollyfield,et al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components , 2012, Nature Medicine.
[11] V. Hornung,et al. Immunology in clinic review series; focus on autoinflammatory diseases: inflammasomes: mechanisms of activation , 2012, Clinical and experimental immunology.
[12] B. Kirchhof,et al. Immunohistochemical localization of complement regulatory proteins in the human retina. , 2012, Histology and histopathology.
[13] V. Cipriani,et al. Age-related macular degeneration and the complement system. , 2012, Immunobiology.
[14] G. Abecasis,et al. Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype. , 2012, International journal of epidemiology.
[15] Santa Jeremy Ono,et al. Serum autoantibody biomarkers for age-related macular degeneration and possible regulators of neovascularization. , 2012, Experimental and molecular pathology.
[16] Kang Zhang,et al. Genetics of Immunological and Inflammatory Components in Age-related Macular Degeneration , 2012, Ocular immunology and inflammation.
[17] A. Sher,et al. Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction , 2012, Nature Immunology.
[18] C. Glass,et al. Microglial cell origin and phenotypes in health and disease , 2011, Nature Reviews Immunology.
[19] Sivakumar Gowrisankar,et al. A rare penetrant mutation in CFH confers high risk of age-related macular degeneration , 2011, Nature Genetics.
[20] P. Charbel Issa,et al. Complement Regulation at Necrotic Cell Lesions Is Impaired by the Age-Related Macular Degeneration-Associated Factor-H His402 Risk Variant , 2011, The Journal of Immunology.
[21] P. Menu,et al. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly , 2011, Clinical and experimental immunology.
[22] J. Tschopp,et al. The inflammasome: an integrated view , 2011, Immunological reviews.
[23] E. Agrón,et al. Complement component C5a Promotes Expression of IL-22 and IL-17 from Human T cells and its Implication in Age-related Macular Degeneration , 2011, Journal of Translational Medicine.
[24] D. Fearon,et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk , 2011, Proceedings of the National Academy of Sciences.
[25] S. Cashman,et al. A Non Membrane-Targeted Human Soluble CD59 Attenuates Choroidal Neovascularization in a Model of Age Related Macular Degeneration , 2011, PloS one.
[26] S. Tomlinson,et al. The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization. , 2011, Molecular immunology.
[27] S. Ryter,et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. , 2011, Nature immunology.
[28] I. Deary,et al. Complement factor h autoantibodies and age-related macular degeneration. , 2010, Investigative ophthalmology & visual science.
[29] P. Bora,et al. Recombinant Membrane-targeted Form of CD59 Inhibits the Growth of Choroidal Neovascular Complex in Mice* , 2010, The Journal of Biological Chemistry.
[30] Robert B Sim,et al. Impaired Binding of the Age-related Macular Degeneration-associated Complement Factor H 402H Allotype to Bruch's Membrane in Human Retina* , 2010, The Journal of Biological Chemistry.
[31] J. Hollyfield,et al. A Hapten Generated from an Oxidation Fragment of Docosahexaenoic Acid Is Sufficient to Initiate Age-Related Macular Degeneration , 2010, Molecular Neurobiology.
[32] Eric N Brown,et al. Complement, age-related macular degeneration and a vision of the future. , 2010, Archives of ophthalmology.
[33] Don H. Anderson,et al. The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited , 2010, Progress in retinal and eye research.
[34] B. Rosner,et al. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. , 2009, Investigative ophthalmology & visual science.
[35] Santa Jeremy Ono,et al. Autoimmunity in retinal degeneration: autoimmune retinopathy and age-related macular degeneration. , 2009, Journal of autoimmunity.
[36] S. Bressler. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. , 2009, Ophthalmology.
[37] J. Forrester,et al. Para-inflammation in the aging retina , 2009, Progress in Retinal and Eye Research.
[38] G. Gilkeson,et al. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. , 2009, Investigative ophthalmology & visual science.
[39] S. Ichinose,et al. Amyloid‐β up‐regulates complement factor B in retinal pigment epithelial cells through cytokines released from recruited macrophages/microglia: Another mechanism of complement activation in age‐related macular degeneration , 2009, Journal of cellular physiology.
[40] P. Lachmann,et al. Taking Complement to the Clinic – has the Time Finally Come? , 2009, Scandinavian journal of immunology.
[41] Johanna M Seddon,et al. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. , 2009, Investigative ophthalmology & visual science.
[42] S. Rodríguez de Córdoba,et al. Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B , 2009, Proceedings of the National Academy of Sciences.
[43] C. Atkinson,et al. A Novel Targeted Inhibitor of the Alternative Pathway of Complement and Its Therapeutic Application in Ischemia/Reperfusion Injury1 , 2008, The Journal of Immunology.
[44] Martin Oppermann,et al. Systemic Complement Activation in Age-Related Macular Degeneration , 2008, PloS one.
[45] R. Medzhitov. Origin and physiological roles of inflammation , 2008, Nature.
[46] J. Tong,et al. Functional and structural implications of the complement factor H Y402H polymorphism associated with age-related macular degeneration. , 2008, Investigative ophthalmology & visual science.
[47] Joe G Hollyfield,et al. Oxidative damage–induced inflammation initiates age-related macular degeneration , 2008, Nature Medicine.
[48] John D. Lambris,et al. Complement evasion by human pathogens , 2008, Nature Reviews Microbiology.
[49] I. Mantel,et al. Genotype–phenotype correlation of age-related macular degeneration: influence of complement factor H polymorphism , 2008, British Journal of Ophthalmology.
[50] Johanna M Seddon,et al. Variation in complement factor 3 is associated with risk of age-related macular degeneration , 2007, Nature Genetics.
[51] A. Blom,et al. The Factor H Variant Associated with Age-related Macular Degeneration (His-384) and the Non-disease-associated Form Bind Differentially to C-reactive Protein, Fibromodulin, DNA, and Necrotic Cells* , 2007, Journal of Biological Chemistry.
[52] Don H. Anderson,et al. Y402H Polymorphism of Complement Factor H Affects Binding Affinity to C-Reactive Protein1 , 2007, The Journal of Immunology.
[53] P. Bora,et al. CD59, a Complement Regulatory Protein, Controls Choroidal Neovascularization in a Mouse Model of Wet-Type Age-Related Macular Degeneration1 , 2007, The Journal of Immunology.
[54] M. Radeke,et al. Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid , 2006, Proceedings of the National Academy of Sciences.
[55] Johanna M Seddon,et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration , 2006, Nature Genetics.
[56] Victoria A. Higman,et al. His-384 Allotypic Variant of Factor H Associated with Age-related Macular Degeneration Has Different Heparin Binding Properties from the Non-disease-associated Form* , 2006, Journal of Biological Chemistry.
[57] H. Kaplan,et al. Complement Activation via Alternative Pathway Is Critical in the Development of Laser-Induced Choroidal Neovascularization: Role of Factor B and Factor H1 , 2006, The Journal of Immunology.
[58] P. Mitchell,et al. Retinal autoantibody profile in early age‐related macular degeneration: preliminary findings from the Blue Mountains Eye Study , 2006, Clinical & experimental ophthalmology.
[59] A. Hofman,et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. , 2006, JAMA.
[60] T. Goodship,et al. Factor H genotype-phenotype correlations: lessons from aHUS, MPGN II, and AMD. , 2006, Kidney international.
[61] D. Clayton,et al. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. , 2006, Investigative ophthalmology & visual science.
[62] Don H. Anderson,et al. Age‐related macular degeneration—emerging pathogenetic and therapeutic concepts , 2006, Annals of medicine.
[63] Don H. Anderson,et al. Extended haplotypes in the complement factor H (CFH) and CFH‐related (CFHR) family of genes protect against age‐related macular degeneration: Characterization, ethnic distribution and evolutionary implications , 2006, Annals of medicine.
[64] Santa Jeremy Ono,et al. Circulating anti‐retinal antibodies as immune markers in age‐related macular degeneration , 2005, Immunology.
[65] B. Rosner,et al. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. , 2005, Archives of ophthalmology.
[66] R. T. Smith,et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[67] John D Lambris,et al. Drusen complement components C3a and C5a promote choroidal neovascularization. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[68] J. Gilbert,et al. Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration , 2005, Science.
[69] A. Edwards,et al. Complement Factor H Polymorphism and Age-Related Macular Degeneration , 2005, Science.
[70] J. Ott,et al. Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.
[71] T. Olsen,et al. The Minnesota Grading System of eye bank eyes for age-related macular degeneration. , 2004, Investigative ophthalmology & visual science.
[72] A. Dick,et al. Minocycline delays photoreceptor death in the rds mouse through a microglia-independent mechanism. , 2004, Experimental eye research.
[73] P. Jong. Prevalence of age-related macular degeneration in the United States. , 2004 .
[74] A. Dick,et al. CD200 maintains microglial potential to migrate in adult human retinal explant model , 2004, Current eye research.
[75] J. Forrester,et al. Control of myeloid activity during retinal inflammation , 2003, Journal of leukocyte biology.
[76] J. Forrester,et al. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. , 2002, The American journal of pathology.
[77] Robert F Mullins,et al. A role for local inflammation in the formation of drusen in the aging eye. , 2002, American journal of ophthalmology.
[78] L. V. Johnson,et al. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. , 2001, Experimental eye research.
[79] Robert F. Mullins,et al. An Integrated Hypothesis That Considers Drusen as Biomarkers of Immune-Mediated Processes at the RPE-Bruch's Membrane Interface in Aging and Age-Related Macular Degeneration , 2001, Progress in Retinal and Eye Research.
[80] G. Hageman,et al. Structure and composition of drusen associated with glomerulonephritis: Implications for the role of complement activation in drusen biogenesis , 2001, Eye.
[81] M. Gillies,et al. Immunological and Aetiological Aspects of Macular Degeneration , 2001, Progress in Retinal and Eye Research.
[82] A. Dick,et al. IFN-γ and LPS-Mediated IL-10–Dependent Suppression of Retinal Microglial Activation , 2000 .
[83] V. Fischetti,et al. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[84] N. Hamajima,et al. C9-R95X polymorphism in patients with neovascular age-related macular degeneration. , 2012, Investigative ophthalmology & visual science.
[85] P. Zipfel,et al. The role of complement in AMD. , 2010, Advances in experimental medicine and biology.
[86] Cathy Frey,et al. Investigative Ophthalmology and Visual Science , 2010 .
[87] P. Lachmann. The amplification loop of the complement pathways. , 2009, Advances in immunology.
[88] M. Daly,et al. Variation near complement factor I is associated with risk of advanced AMD , 2009, European Journal of Human Genetics.
[89] J. Atkinson,et al. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. , 2007, Advances in immunology.
[90] Don H. Anderson,et al. Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. , 2006, Annals of medicine.
[91] A. Ramé. [Age-related macular degeneration]. , 2006, Revue de l'infirmiere.
[92] Benita J. O’Colmain,et al. Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.